Is PEAR or MRK a better dividend investment in 2026?

PEAR currently yields 6849.32% with a 5% 5-year dividend growth rate. MRK yields 2.76% with 8.2% growth. The better choice depends on your goal: PEAR offers higher current income.

What is the dividend yield difference between PEAR and MRK?

PEAR has a forward dividend yield of 6849.32% ($2.00/share annually). MRK yields 2.76% ($3.32/share annually). The yield gap is 6846.56 percentage points.

Home › Compare › PEAR vs MRK

PEAR vs MRK: Dividend Comparison 2026

PEAR yields 6849.32% · MRK yields 2.76%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 PEAR wins by $1339387406433213.75M in total portfolio value

INVESTMENT

TIME HORIZON10 years

PEAR

● Live price

6849.32%

Share price

$0.03

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$1339387406433213.75M

Annual income

$1,301,993,616,197,644,700,000.00

Full PEAR calculator →

MRK

Merck & Co. Inc.

● Live price

2.76%

Share price

$120.31

Annual div

$3.32

5Y div CAGR

32.7%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$56.8K

Annual income

$9,798.13

Full MRK calculator →

Portfolio growth — PEAR vs MRK

📍 PEAR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	PEAR	MRK
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, PEAR + MRK cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

PEAR pays

MRK pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PEAR

Annual income on $10K today (after 15% tax)

$582,191.78/yr

After 10yr DRIP, annual income (after tax)

$1,106,694,573,767,997,900,000.00/yr

MRK

Annual income on $10K today (after 15% tax)

$234.56/yr

After 10yr DRIP, annual income (after tax)

$8,328.41/yr

At 15% tax rate, PEAR beats the other by $1,106,694,573,767,997,900,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PEAR + MRK for your $10,000?

PEAR: 50%MRK: 50%

100% MRK50/50100% PEAR

Portfolio after 10yr

$669693703216606.88M

Annual income

$650,996,808,098,822,400,000.00/yr

Blended yield

97.21%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

PEAR

Analyst Ratings

Buy

Hold

Consensus: Hold

Price Target

$6.50

+22160.3% upside vs current

Range: $5.00 — $8.00

Altman Z

-8.5

Piotroski

4/9

MRK

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$128.54

+6.8% upside vs current

Range: $100.00 — $150.00

Altman Z

4.0

Piotroski

6/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PEAR buys

MRK buys

No recent congressional trades found for PEAR or MRK in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricPEARMRK

Forward yield	6849.32% ✓	2.76%
Annual dividend / share	$2.00	$3.32 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	32.7% ✓
Portfolio after 10y	$1339387406433213.75M ✓	$56.8K
Annual income after 10y	$1,301,993,616,197,644,700,000.00 ✓	$9,798.13
Total dividends collected	$1336879923883212.75M ✓	$28.9K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare
Analyst consensus	Hold	Buy
Analyst price target	$6.50	$128.54 ✓

Year-by-year: PEAR vs MRK ($10,000, DRIP)

Year	PEAR Portfolio	PEAR Income/yr	MRK Portfolio	MRK Income/yr	Gap
1← crossover	$695,632	$684,931.51	$11,206	$366.19	+$684.4K → PEAR
2	$45,273,292	$44,528,966.00	$12,650	$502.35	+$45.26M → PEAR
3	$2,756,897,651	$2,708,455,228.62	$14,407	$694.19	+$2756.88M → PEAR
4	$157,090,270,836	$154,140,390,350.12	$16,585	$967.82	+$157090.25M → PEAR
5	$8,376,539,704,888	$8,208,453,115,093.00	$19,342	$1,363.89	+$8376539.69M → PEAR
6	$418,028,448,270,623	$409,065,550,786,392.40	$22,913	$1,947.19	+$418028448.25M → PEAR
7	$19,526,057,962,883,308	$19,078,767,523,233,740.00	$27,662	$2,823.89	+$19526057962.86M → PEAR
8	$853,759,153,007,212,900	$832,866,270,986,927,700.00	$34,159	$4,173.35	+$853759153007.18M → PEAR
9	$34,947,467,509,877,550,000	$34,033,945,216,159,830,000.00	$43,337	$6,308.80	+$34947467509877.51M → PEAR
10	$1,339,387,406,433,213,700,000	$1,301,993,616,197,644,700,000.00	$56,776	$9,798.13	+$1339387406433213.75M → PEAR

PEAR vs MRK: Complete Analysis 2026

PEAR — Stock

Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.

Full PEAR Calculator →

MRK — Healthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →

📬

Get this PEAR vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PEAR vs SCHD PEAR vs JEPI PEAR vs O PEAR vs KO PEAR vs MAIN PEAR vs JNJ PEAR vs ABBV PEAR vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.